Efficacy summary in the overall population (N = 90) with mosunetuzumab
| INV-assessed efficacy end points . | Mosunetuzumab (N = 90) . |
|---|---|
| ORR∗ % (95% CI) | 77.8 (67.8-85.9) |
| CR∗ % (95% CI) | 60.0 (49.1-70.2) |
| Time to first response, mo, median (range) | 1.4 (1-11) |
| Time to first CR, mo, median (range) | 3.0 (1-19) |
| DOR, mo, median (95% CI) (n = 70) | 35.9 (20.7-NE) |
| 30-mo remission rate, % (95% CI) | 56.6 (44.2-68.9) |
| DOCR, mo, median (95% CI) (n = 54) | NR (33.0-NE) |
| 30-mo remission rate, % (95% CI) | 72.4 (59.2-85.6) |
| PFS, mo, median (95% CI) | 24.0 (12.0-NE) |
| 36-mo PFS rate, % (95% CI) | 43.2 (31.3-55.2) |
| OS, mo, median (95% CI) | NR (NE-NE) |
| 36-mo OS rate, % (95% CI) | 82.4 (73.8-91.0) |
| TTNT, mo, median (95% CI) | 37.3 (18.0-NE) |
| 36-mo TTNT rate, % (95% CI) | 51.8 (40.8-62.8) |
| INV-assessed efficacy end points . | Mosunetuzumab (N = 90) . |
|---|---|
| ORR∗ % (95% CI) | 77.8 (67.8-85.9) |
| CR∗ % (95% CI) | 60.0 (49.1-70.2) |
| Time to first response, mo, median (range) | 1.4 (1-11) |
| Time to first CR, mo, median (range) | 3.0 (1-19) |
| DOR, mo, median (95% CI) (n = 70) | 35.9 (20.7-NE) |
| 30-mo remission rate, % (95% CI) | 56.6 (44.2-68.9) |
| DOCR, mo, median (95% CI) (n = 54) | NR (33.0-NE) |
| 30-mo remission rate, % (95% CI) | 72.4 (59.2-85.6) |
| PFS, mo, median (95% CI) | 24.0 (12.0-NE) |
| 36-mo PFS rate, % (95% CI) | 43.2 (31.3-55.2) |
| OS, mo, median (95% CI) | NR (NE-NE) |
| 36-mo OS rate, % (95% CI) | 82.4 (73.8-91.0) |
| TTNT, mo, median (95% CI) | 37.3 (18.0-NE) |
| 36-mo TTNT rate, % (95% CI) | 51.8 (40.8-62.8) |